CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced data from Preclinical studies of its investigational SARS-CoV-2 Vaccine candidate, CVnCoV, in mice and hamsters. The vaccine candidate elicited balanced humoral and cellular immune responses, featuring high antibody titers and very good […]
Source
This post first appeared on Fav Store – Herbal Products And News, please read the originial post: here
